Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.

J Infect Dis. 2000 Apr;181(4):1273-9. Unique Identifier : AIDSLINE MED/20294194
Dybul M; Chun TW; Ward DJ; Hertogs K; Larder B; Fox CH; Orenstein JM; Baird BF; Li Y; Green LG; Engel D; Liu S; Mican JM; Fauci AS; Laboratory of Immunoregulation, National Institute of Allergy and; Infectious Diseases, National Institute of Health, Bethesda, MD; 20892, USA. mdybul@nih.gov

Abstract: Although efavirenz-containing regimens effectively suppress plasma levels of human immunodeficiency virus (HIV) RNA, it is now clear that undetectable plasma viremia may not reflect a lack of viral replication. Because lymphoid tissue is an active site of HIV replication, the lymph node virus burden was analyzed in persons who received highly active antiretroviral therapy (HAART) containing either efavirenz or a protease inhibitor (PI). Testing with in situ hybridization revealed no detectable follicular dendritic cell-associated HIV RNA in either group, and only 2 of 8 persons in the efavirenz group and 1 of 4 in the PI group had detectable RNA in lymph node mononuclear cells (LNMC) when tested by use of nucleic acid sequencebased amplification. Low levels of replication-competent HIV were identified in both groups by use of quantitative coculture assays. There was no evidence of development of resistance to either regimen in virus isolated from LNMC. These data support the use of efavirenz as an alternative to a PI in initial HAART regimens.

Keywords: CLINICAL TRIAL JOURNAL ARTICLE Anti-HIV Agents/*THERAPEUTIC USE Coculture Cross-Sectional Studies Genotype Human HIV/GENETICS/PHYSIOLOGY HIV Infections/DRUG THERAPY/PATHOLOGY/*VIROLOGY In Situ Hybridization Lymph Nodes/PATHOLOGY/*VIROLOGY Oxazines/*THERAPEUTIC USE Protease Inhibitors/THERAPEUTIC USE Reverse Transcriptase Inhibitors/*THERAPEUTIC USE RNA, Viral/ANALYSIS Viral Load Virus Replication

000830
A0080957

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .